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formulation of an intervention to cooperate between cardiology
and gastroenterology departments of the hospital and to explore
the truths behind Hepatitis-B effecting multiorgan systems.
Methods: Cross-sectional analytical study was conducted at PIMS
Hospital, Islamabad from March 2007 to August 2008. Conﬁrmed
cirrhotic end-stage liver disease HEP-B patients were recruited.
An equal numbers of non-cirrhotics were also taken as control.
ECG was recorded and values of HR and QTc were calculated.
Comparison of increased frequency of HR and prolongation of QTc
were done using Chi-square (biostatistical) Test with signiﬁcance
level at 0.05 and using SPSS15 software. Curves of HR and QTc
were plotted for the presence of cirrhosis.
Results: 78 conﬁrmed patients of HEP-B cirrhosis of liver along
with the same number of non-cirrhotic patients as control. The
mean ± SD of QTc of cirrhotic Group was 0.438±0.015 sec and
that in non-cirrhotic group was 0.432±0.010 sec and that for HR
in cirrhotic and non cirrhotic were 78.34±12.15 and 74.98±8.03
beats/min respectively. The mean QTc and HR values were signif-
icantly more among cirrhotic as compared to non cirrhotic with
p=0.006 and p=0.043 respectively.
Conclusion: Means of both HR and QTc were signiﬁcantly higher
in cirrhotic patients as compared with non-cirrhotic controls.
The data can be used in future in making and correlating cardiac
diseases with liver problems specially hepatitis B infections.
PP-044 Study on characteristics of Th17 in
HBV-associated acute on chronic liver failure
patients and the correlation with prognosis
Fang Lin*, Jiyuan Zhang, Huifen Wang, Fusheng Wang. Beijing
302 Hospital, Beijing, PR China
Background: People’s health were threatened by hepatitis B
virus-associated acute on chronic liver failure (HBV-ACLF). No
one reported the characteristics of Th17 in HBV-ACLF patients
and the immunological markers related to prognosis of HBV-ACLF
are lack.
Methods: Th17 frequency and IL-17 levels were measured on
admission in 48 HBV-ACLF, 40 chronic hepatitis B (CHB)and 38
decompensated cirrhosis (HBV-LC) patients without bacteria or
fungus infection simultaneously, 23 heathy cases (HC) were con-
trolled. Th17 frequency, as well as the plasma concentration of
IL-17 and liver tissue in situ IL-17 expression were compared
among the four different groups. Dynamic deteciotns of Th17
frequency of 48 HBV-ACLF patients on 2, 4 and 12weeks.
Result: Th17 frequency and IL-17 concentration in peripheral
blood of HBV-ACLF patients were higher than HBV group, HBV-
LC group and the healthy control group. Intrahepatic in situ
expressions of IL-17 in ACLF group were higher than those in
CHB, HBV-LC and HC. The Th17 frequency in peripheral blood
of survival ACLF patients were signiﬁcantly lower than the non-
survival patients. The frequency of Th17 decreased gradually in
survival group, Th17 frequency of non-survival group increased.
The frequencies of Th17 changes of 2 weeks to admission were
correlated with the prognosis in HBV-ACLF patients.
Conclusion: Th17 and IL-17 expressions increase in HBV-ACLF
patients. Th17 can be served as an immunological marker of
prognosis in HBV-ACLF patients.
PP-045 Effect of combination millimeter wave irradiation
on hepatic cellular cancer patient
Jinglong Chen*. Beijing Ditan Hospital, Beijing, China
Objectives: Combination MWI (millimeter wave irradiation)
called IZL-2003 immunotherapy system irradiate marrow and
Chinese channel and point, The aim was to promote bone mar-
row cell regeneration or proliferation, and increased white blood
cell count, improve patient’s quality of life and tumor immunity
function.
Methods: there was 61 selected HCC patients, 40 cases of the
total was in treatment group, MWI and general liver aids was
administered together, 21 cases was as control group with only
general liver aids, combination MWI include constant amplitude
EHF (extremely high frequency), pulse EHF and poly-energy EHF,
Irradiation frequency was between 35GHz and 42.8 GHz.
Results:MWI increased white blood cell count and haematoglobin
level for HCC patients with lower white blood cell, P value was
0.028 and 0.017 respectively, T cell subgroup CD4+ count was
raised after MWI, when CD4+ count was below 400 cells/μl, CD4+
count was raised signiﬁcantly. Otherwise, MWI improve effec-
tively symptom, appetite, physical capacity and other quality of
life. So it raised Karnofsky score, effective rate was above 80%,
P<0.05.
Conclusion: MWI increased white blood cell and haematoglobin
level for HCC patients with lower white blood cell. It was adapt
to the patient with lower white blood cell and anaemia, and
improved immunity function and other quality of life. It will be
Cooperated with radiotherapy and chemotherapy without trauma
and side effect for patients.
PP-046 The clinical features of hepatogenous diabetes
Chunyan Jiang*. Comprehensive Department, Beijing Friendship
Hospital, Capital Medical University, Beijing, China
Objectives: To investigate the clinical features and the possible
etiology of hepatogenous diabetes.
Methods: One hundred and two cases with hepatogenous dia-
betes were retrospectively analyzed and compared with those of
primary type 2 diabetes mellitus.
Results:Only 17% of patients with hepatogenous diabetes showed
the typical diabetic symptoms such as dry mouth, polydipsia,
polyphagia, polyuria, et al. The patients with hepatogenous dia-
betes showed fasting plasma glucose (FPG) as (7.8±2.6) mmol/L
and postprandial plasma glucose (PPG) as (12.7±3.0)mmol/L.
In oral glucose tolerance test (OGTT), The patients with hep-
atogenous diabetes showed a much lower level of FPG than
that of primary type 2 diabetes mellitus (P<0.01). In insulin
and C-peptide release test, both the two groups showed a de-
layed insulin peak, but the patients with hepatogenous diabetes
showed higher insulin values at all the four periods of time than
those of primary type 2 diabetes mellitus (P<0.05). After the
treatment of diet control together with the use of insulin or
other oral drugs, most patients showed normal or near normal
levels of blood glucose. Only 5 cases had diabetic complications,
and 4 cases died of complications of underlying chronic hepatic
diseases.
Conclusion: The hepatogenous diabetes is clinically asymp-
tomatic, and is characterized by higher PPG. The insulin treat-
ment is effective for the patients with hepatogenous diabetes,
and the short-time poor prognosis is more likely to be affected
by the underlying hepatic disease. Insulin resistance may play a
central role in the etiology of the hepatogenous diabetes.
PP-047 Naloxone in the management of hepatic
encephalopathy
Ming-Hua Zheng*,1, Qian Jiang2, Ke-Qing Shi 1, Yong-Ping Chen1.
1Department of Infection and Liver Diseases, The First Afﬁliated
Hospital of Wenzhou Medical College; 2Department of Clinical
Pharmacy, West China School of Pharmacy, Sichuan University
Objectives: This study aimed to assess the effectiveness and
safety of naloxone in the management of hepatic encephalopa-
thy.
Methods: We employed the method recommended by the
Cochrane Collaboration to perform a meta-analysis of ran-
domized controlled trials of naloxone therapy for hepatic en-
cephalopathy including 17 randomized controlled trials.
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Results: 15 randomized trials randomizing 1054 patients were
analyzed. Naloxone had signiﬁcant effect on improvement of
hepatic encephalopathy (relative risk 1.46; 95 percent CI 1.27 to
1.67; P = 0.0005). This comparison showed signiﬁcantly statisti-
cal heterogeneity (P = 0.10, and χ2= 44.93). Subgroup analysis
showed that naloxone administered both by injected and infusion
route could be effective (relative risk 1.34; 95 percent CI 1.17
to 1.53; P = 0.0001) and there was signiﬁcant effect in trials
by infusion route (relative risk 1.42; 95 percent CI 1.19 to 1.69;
P = 0.0001). Adverse effects were observed in only 8 patients
treated with naloxone.
Conclusion: Naloxone could get patients with hepatic en-
cephalopathy improved, however because of the studies were of
generally poor quality, we are unable to make ﬁrm conclusions. It
is possible that further investigation in well-designed trials may
help conﬁrm our results.
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PP-048 Autoimmune hepatitis complicated with Sjögren’s
syndrome: a case report
Ying-Qiong Peng1, Meng-Hou Lu*,1,2. 1Department of Infectious
Diseases, Xiangya Hospital, Central-South University, Xiangya
Road, Changsha, Hunan, PR China; 2Department of Infectious
Diseases, Xiangya Hospital, Central-South University
Introduction: Sjogren syndrome (SS) is a chronic autoimmune
disorder that may affects salivary, lachrymal glands, liver, blood,
joints and others with diverse clinical manifestations. We pre-
sented a case of autoimmune hepatitis complicated with SS,
which mainly presented recurrent abnormal liver enzyme tests
of unknown origin.
Case description: A 45-year-old woman had a 5-month his-
tory of recurrent weakness and anorexia, and 15-day history
of jaundice. Physical examination revealed moderate jaundice.
Laboratory ﬁndings revealed hepatic dysfunction, including high
level aspartate aminotransferase 999.1 IU/L, alanine amino-
transferase 597.8 IU/L, direct bilirubin 51.8 mg/dl, and total
bilirubin 95.2 mg/dl. The titer of anti-nuclear antibody is 1:320.
Multiple antibodies were negative, including anti-hepatitis A,
B, C, E viruses, Anti-double chain DNA, mitochondrial antibody,
smooth-muscle autoantibody, anti-neutrophil cytoplasmic anti-
body, and anti-SSA/B antibody. Histologic examination of liver
showed hydropic degeneration of some hepatocytes. Inﬂamma-
tory cells were observed in portal areas. Biopsy of salivary labial
gland demonstrated sialoadenitis. Positive ﬂuorescent stain of
the right cornea. Those conﬁrmed the diagnosis of autoimmune
hepatitis complicated with SS.
SS is not uncommon. Patients with hyperglobulinemias, ram-
pant caries, ophthalmos purulent discharge, recurrent parotid
enlargement, joint pain, recurrent abnormal liver enzyme or
jaundice of unknown origin, and all suspected virual hepati-
tis should be asked about the history of oral or eye dryness.
If necessary, anti-nuclear, anti-SSA/B antibody, salivary gland
biopsy, corneal ﬂuorescent exam, and parotid imagery should be
obtained to minimize misdiagnosis.
PP-049 The immunostaining of programmed death 1
(PD-1) and its ligands in liver tissues of patients
with hepatitis and hepatocellular carcinoma
Baoju Wang*,1, Junjie Bao1,2, Min Jiang3, Junzhong Wang1,
Yang Wang1, Mingyou Xing4, Wanguang Zhang5, Junying Qi4,
Michael Roggendorf6, Mengji Lu6, Dongliang Yang1. 1Division of
Clinical Immunology, Tongji Hospital of Tongji Medical College,
Huazhong University of Science and Technology, Wuhan, China;
2Guangzhou Women and Children’s Medical Center, Guangzhou,
China; 3Department of Microbiology, Tongji Medical College,
Huazhong University of Science and Technology, Wuhan, China;
4Department of Infectious Disease, Tongji Hospital of Tongji
Medical College, Huazhong University of Science and
Technology, Wuhan, China; 5Hepatic Surgery Center, Tongji
Hospital of Tongji Medical College, Huazhong University of
Science and Technology, Wuhan, China; 6Institut für Virologie,
Universitätsklinkum Essen, Essen, Germany
Goals: The programmed death 1 (PD-1) and its ligands (PD-L1
and PD-L2) are known as a system for negative regulation of
T-cell activation. Recent investigations indicated the PD-1/PD-Ls
system plays a signiﬁcant role in persistent viral infection and
tumor development. Thus, it is warrant to investigate the ex-
pression of PD-1, PD-L1 and -2 in liver tissues in the context of
chronic hepatitis and those of hepatocellular carcinomas (HCC)
and evaluated their relationships with clinical and pathological
variables.
Study: Liver biopsies and HCC specimens from patients were
collected and histologically examined. The expression of PD-1,
PD-L1, and PD-L2 in biopsy specimens of chronic hepatitis and of
HCC specimens was evaluated by immunohistochemical staining.
Results: The expression of PD-1 was found in liver inﬁltrated
lymphocytes. In the contrast, PD-L1 and -L2 were expressed in
Kupffer cells, liver sinoidal endothetial cells (LSECs), and tumor
cells. The expression of PD-L1 was signiﬁcantly correlated with
HBV infection and with the stage of HCC. PD-1 and PD-Ls were
signiﬁcantly up-regulated in HCC specimens.
Conclusions: The intrahepatic expression of PD-L1 was signiﬁ-
cantly up-regulated in HBV infection, suggesting that the PD-L1
may contribute to negative regulation of immune response in
chronic hepatitis B. It is worthy to examine whether the high
level expression of PD-1 and PD-Ls in HCC specimens play a role
in the carcinogenesis and immune evasion of tumors.
PP-050 Alpha-fetoprotein induced phosphorylation of
AKT via inhibited the activity of PTEN in human
hepatoma Bel 7402 cells
Mengsen Li *,1,2, Sheng Zhou1, Mingyue Zhu1, Xiaoying Wang1,
Xinhua Liu2, Gang Li 2. 1Key Laboratory of Molecular Biology,
Hainan Medical College; 2Department of Biochemistry and
Molecular Biology, Peking University Health Science Center
Objective: The events of hepetocellular cancinoma cells (HCC)
correlated to infection of hepatitis virus. PTEN/AKT signal path-
way plays a central role in the proliferation of the tumor cells.
The present investigation purpose to explore alpha-fetoprotein
(AFP) inﬂuences on the transduction of PTEN/AKT signal pathway
in HCC.
Methods: Western Blotting was utilized to detecting the expres-
sion of PTEN and the phosphorylation of protein kinase B (AKT)
in Bel 7402 cells. AFP interacted with PTEN was analyzed by
co-immunoprecipitation (Co-IP); Laser confocal microscopy was
used to observe co-localization of AFP with PTEN and the ﬂuores-
cence resonance energy transfer (FRET) of FITC (labeled PTEN)
and TRITC (labeled AFP); Short small RNA interfering (RNAi) was
applied to block the expression of AFP.
Results: All trans retinoic acid (ATRA) (160μmol/L) mildly pro-
moted the expression of PTEN in Bel 7402 cells; Co-IP indicated
that AFP could interact with PTEN, co-localization of PTEN and
